Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug ...Middle East

PR Newswire - News
Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug
Proof of Concept (POC) in-human trial to take place at Rambam Health Care Campus in Israel throughout 2022 REHOVOT, Israel, July 11, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd....

Hence then, the article about biomica announces successful enrollment of first patient in its phase i study of microbiome based immuno oncology drug was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News